Witnesses warn FDA staffing cuts and slowed inspections would worsen drug shortages and safety risks
Get AI-powered insights, summaries, and transcripts
Subscribe
Summary
Multiple witnesses and members told the House Energy and Commerce subcommittee that proposed agency layoffs and paused guidance work at FDA could delay approvals and inspections, aggravating drug shortages and undermining efforts to reshore production.
Lawmakers and witnesses at a House subcommittee hearing raised alarms about proposed staffing reductions and reorganization at the Food and Drug Administration and said diminished inspection and regulatory capacity would hamper efforts to secure domestic pharmaceutical production and ensure drug quality.
Ranking members and witnesses repeatedly warned that inspection capacity and policy guidance are critical to safe domestic production. Representative Frank Pallone and Representative Diana DeGette highlighted that layoffs and paused work on generic drug guidance would make it harder to address shortages and rebuild domestic manufacturing.
Key testimony and exchanges: - Representative Pallone said recent firings and reorganization at HHS and FDA “put the health and well‑being of the American people...at extreme risk,” and urged robust oversight of agency actions. - USP’s Ronald Piervincenzi and the Association for Accessible Medicines’ John Murphy said strong FDA inspections and product‑specific guidances are essential. Murphy noted that delays in releasing product‑specific guidances had already created backlogs and slowdowns in generic development; he welcomed the agency’s steps to resume issuing guidance but said capacity is still needed. - Witnesses described that reduced inspection capacity could slow approval and restart of domestic lines and overseas inspections, limiting both safety assurance and the ability to rely on reshored production.
Why it matters: FDA inspection and regulatory review are prerequisites to bringing new or retooled domestic facilities into operation. Witnesses said that without stable inspection staffing and timely guidance, manufacturers cannot confidently invest in U.S. production and the risk of poor quality or counterfeit products entering the supply chain rises.
Ending: Witnesses and several members urged Congress to fund FDA inspection capacity and provide the agency with stable resources so inspections and guidance can keep pace with efforts to onshore production and respond to shortages.